Immorta Bio Presents SenoVax™ Mediated Tumor Remission Data at International Biotechnology Conference

Scientific Longevity Company Provides Updates on its Oncology Program at LSX Investival Showcase

MIAMI, March 13, 2025 /PRNewswire/ -- Immorta Bio Inc., a scientific longevity company focused on "Treating Diseases of Aging and Treating Aging as Disease™," announced today that its Chairman and CEO, Dr. Boris Reznik, presented the latest findings from its SenoVax™ Program at the LSX Investival Showcase on March 11^th at the Miami Beach Convention Centre. 

The presentation disclosed advancements in the Company's oncology pipeline, highlighting animal studies showing the regression of brain, lung, skin, pancreas, and breast cancers by SenoVax™, the Company's lead product. Additionally, cellular mechanisms by which this "longevity therapeutic" targets a broad range of cancers were discussed. 

"It has been widely demonstrated that senescent cells play a critical role in initiating, promoting and protecting cancer," said Dr. Thomas Ichim, President and Chief Scientific Officer of the Company. "By amplifying the body's natural immunological activities to kill senescent cells, SenoVax™ induces regression of tumors."

The Company, together with the University of California San Diego, George Washington University, Calidi Biosciences, and Cedars Sinai, demonstrated in a peer-reviewed publication that SenoVax™ kills cancer in part by inducing antibody and T cell responses that eliminate senescent cells¹.

"We are developing multiple programs focused on radical extension of human healthspan including our senolytic immunotherapy platform," said Dr. Boris Reznik, Chairman and CEO of Immorta Bio. "Our development strategy is to apply longevity-associated technologies to address unmet medical needs that can provide answers in months not decades."

About Immorta Bio Immorta Bio Inc., a scientific longevity company focused on "Treating Diseases of Aging and Treating Aging as Disease™," leverages anti-aging technologies to tackle pressing medical challenges, from advanced cancers to other age-related conditions. To learn more about Immorta Bio' research initiatives, visit immortabio.com, LinkedIn and X.

Company Contact
Dr. Boris Reznik
Immorta Bio
https://www.immortabio.com
+1 305-632-2939
@immortabio

¹ https://medcraveonline.com/JSRT/JSRT-09-00169.pdf

SOURCE Immorta Bio Inc.